These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 31243222

  • 1. Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.
    Inomata S, Anan A, Yamauchi E, Yamauchi R, Kunimoto H, Takata K, Tanaka T, Yokoyama K, Morihara D, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S.
    Intern Med; 2019 Oct 15; 58(20):2915-2922. PubMed ID: 31243222
    [Abstract] [Full Text] [Related]

  • 2. Male-specific Association between Iron and Lipid Metabolism Changes and Erythroferrone after Hepatitis C Virus Eradication.
    Inomata S, Morihara D, Anan A, Yamauchi E, Yamauchi R, Takata K, Tanaka T, Yokoyama K, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S, Hirai F.
    Intern Med; 2022 Feb 15; 61(4):461-467. PubMed ID: 34433710
    [Abstract] [Full Text] [Related]

  • 3. Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell disease.
    Mangaonkar AA, Thawer F, Son J, Ajebo G, Xu H, Barrett NJ, Wells LG, Bowman L, Clair B, Patel N, Bora P, Jung G, Nemeth E, Kutlar A.
    Br J Haematol; 2020 Jun 15; 189(6):1204-1209. PubMed ID: 32030737
    [Abstract] [Full Text] [Related]

  • 4. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.
    Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, Iwasa M, Kobayashi Y, Hayashi H, Kaito M, Takei Y.
    J Hepatol; 2008 Nov 15; 49(5):702-10. PubMed ID: 18620776
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Marathon Run-induced Changes in the Erythropoietin-Erythroferrone-Hepcidin Axis are Iron Dependent.
    Tomczyk M, Kortas J, Flis D, Kaczorowska-Hac B, Grzybkowska A, Borkowska A, Lewicka E, Dabrowska-Kugacka A, Antosiewicz J.
    Int J Environ Res Public Health; 2020 Apr 17; 17(8):. PubMed ID: 32316587
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.
    Pirotte M, Fillet M, Seidel L, Jaspers A, Baron F, Beguin Y.
    Am J Hematol; 2021 Oct 01; 96(10):1275-1286. PubMed ID: 34310730
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of Erythroferrone, Hepcidin, and Iron Overload Status in Iraqi Transfusion-Dependent β-Thalassemia Major Patients.
    Smesam HNK, Albuthabhak HAQ, Arjmand S, Al-Hakeim HK, R Siadat SO.
    Hemoglobin; 2020 Jul 01; 44(4):272-277. PubMed ID: 32718192
    [Abstract] [Full Text] [Related]

  • 14. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC.
    Gut; 2018 Jul 01; 67(7):1342-1350. PubMed ID: 28615303
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL, Xu GH, Zhang JY, Li W, Zhang DW, Li ZQ, Liang HX, Li CX, Yu ZJ.
    J Hepatol; 2017 Jun 01; 66(6):1123-1129. PubMed ID: 28189754
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Alterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency.
    Foka P, Dimitriadis A, Karamichali E, Kyratzopoulou E, Giannimaras D, Koskinas J, Varaklioti A, Mamalaki A, Georgopoulou U.
    Virulence; 2016 Aug 17; 7(6):679-90. PubMed ID: 27058404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.